Core Insights - Puyi Bio has completed a 150 million RMB Series B financing round, aimed at enhancing its core technology iteration, capacity construction, medical device registration, and market expansion, thereby strengthening its competitiveness in nanopore gene sequencing [2][1] Group 1: Financing and Strategic Focus - The financing will focus on four key areas: core technology iteration, scalable capacity construction, medical device registration, and global market expansion [2] - This financing marks a significant recognition from the capital market regarding the company's capabilities in independent controllable underlying technology and commercial achievements [2] Group 2: Technological Advancements - Puyi Bio is one of the few domestic high-tech companies that possess independent intellectual property across the entire chain of "sequencing chemistry - sequencing chip - instrument system - supporting reagents" [2] - The company has achieved key technological breakthroughs in four core areas of nanopore sequencing, including nanopore protein modification, single-molecule base recognition, highly integrated silicon-based chips, and high-fidelity signal acquisition systems [2] - The core reagents have achieved 100% domestic controllability, establishing a complete technological moat from fundamental research to mass production [2]